Clinical relevance and concordance of HER2 status in local and central testing: an analysis of 1581 HER2-positive breast carcinomas over 12 years
Human epidermal growth factor receptor 2 (HER2) is a central predictive biomarker in breast cancer. Inaccurate HER2 results in different laboratories could be as high as 20%. However, this statement is based on data generated more than 13 years ago and may not reflect the standards of modern diagnos...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 2018
|
| In: |
Modern pathology
Year: 2018, Jahrgang: 31, Heft: 4, Pages: 607-615 |
| ISSN: | 1530-0285 |
| DOI: | 10.1038/modpathol.2017.171 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1038/modpathol.2017.171 Verlag, Volltext: https://www.nature.com/articles/modpathol2017171 
|
| Verfasserangaben: | Berit M. Pfitzner, Bianca Lederer, Judith Lindner, Christine Solbach, Knut Engels, Mahdi Rezai, Karel Dohnal, Hans Tesch, Martin L. Hansmann, Christoph Salat, Michaela Beer, Andreas Schneeweiss, Peter Sinn, Agnes Bankfalvi, Silvia Darb-Esfahani, Gunter von Minckwitz, Bruno V. Sinn, Ralf Kronenwett, Karsten Weber, Carsten Denkert, & Sibylle Loibl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1583752137 | ||
| 003 | DE-627 | ||
| 005 | 20230427161316.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181115s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/modpathol.2017.171 |2 doi | |
| 035 | |a (DE-627)1583752137 | ||
| 035 | |a (DE-576)513752137 | ||
| 035 | |a (DE-599)BSZ513752137 | ||
| 035 | |a (OCoLC)1341023550 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pfitzner, Berit Maria |d 1979- |e VerfasserIn |0 (DE-588)130009776 |0 (DE-627)487569318 |0 (DE-576)297948679 |4 aut | |
| 245 | 1 | 0 | |a Clinical relevance and concordance of HER2 status in local and central testing |b an analysis of 1581 HER2-positive breast carcinomas over 12 years |c Berit M. Pfitzner, Bianca Lederer, Judith Lindner, Christine Solbach, Knut Engels, Mahdi Rezai, Karel Dohnal, Hans Tesch, Martin L. Hansmann, Christoph Salat, Michaela Beer, Andreas Schneeweiss, Peter Sinn, Agnes Bankfalvi, Silvia Darb-Esfahani, Gunter von Minckwitz, Bruno V. Sinn, Ralf Kronenwett, Karsten Weber, Carsten Denkert, & Sibylle Loibl |
| 264 | 1 | |c April 2018 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published: 22 December 2017 | ||
| 500 | |a Gesehen am 15.11.2018 | ||
| 520 | |a Human epidermal growth factor receptor 2 (HER2) is a central predictive biomarker in breast cancer. Inaccurate HER2 results in different laboratories could be as high as 20%. However, this statement is based on data generated more than 13 years ago and may not reflect the standards of modern diagnostic pathology. We compared central and local HER2 testing in a total of 1581 HER2-positive tumors from five clinical trials. We evaluated the clinical relevance for pathological complete response (pCR) and disease-free survival in a subgroup of 677 tumors, which received an anti-HER2 therapy. Over the period of 12 years, the discordance rate for HER2 decreased from 52.4 (GeparTrio) to 8.4% (GeparSepto). Discordance rates were significantly higher in hormone receptor (HR)-positive tumors (26.6%), compared to HR-negative tumors (16.3%, P<0.0001), which could be explained by a different distribution of HER2 mRNA levels in HR-positive and HR-negative tumors. pCR rates were significantly lower in discordant tumors (13.7%) compared to concordant tumors (32.2%, GeparQuattro and GeparQuinto, P<0.001). In survival analysis, tumors with discordant HER2 testing had a reduced overall survival (OS) in the HR-negative group (P=0.019) and a trend for improved OS in the HR-positive group (P=0.125). The performance of local HER2 testing was considerably improved over time and has reached a 92% concordance, which shows that quality initiatives in diagnostic pathology are working. Tumors with discordant HER2 testing had a reduced therapy response and different survival rates. | ||
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Sinn, Peter |d 1957- |e VerfasserIn |0 (DE-588)1022590944 |0 (DE-627)717004783 |0 (DE-576)365646342 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Modern pathology |d London : Nature Publishing Group, 1988 |g 31(2018), 4, Seite 607-615 |h Online-Ressource |w (DE-627)326643419 |w (DE-600)2041318-X |w (DE-576)283165553 |x 1530-0285 |7 nnas |a Clinical relevance and concordance of HER2 status in local and central testing an analysis of 1581 HER2-positive breast carcinomas over 12 years |
| 773 | 1 | 8 | |g volume:31 |g year:2018 |g number:4 |g pages:607-615 |g extent:9 |a Clinical relevance and concordance of HER2 status in local and central testing an analysis of 1581 HER2-positive breast carcinomas over 12 years |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/modpathol.2017.171 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/modpathol2017171 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181115 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1022590944 |a Sinn, Peter |m 1022590944:Sinn, Peter |d 910000 |d 912000 |e 910000PS1022590944 |e 912000PS1022590944 |k 0/910000/ |k 1/910000/912000/ |p 13 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 12 | ||
| 999 | |a KXP-PPN1583752137 |e 3032436761 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1583752137","title":[{"title":"Clinical relevance and concordance of HER2 status in local and central testing","title_sort":"Clinical relevance and concordance of HER2 status in local and central testing","subtitle":"an analysis of 1581 HER2-positive breast carcinomas over 12 years"}],"physDesc":[{"extent":"9 S."}],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"April 2018"}],"name":{"displayForm":["Berit M. Pfitzner, Bianca Lederer, Judith Lindner, Christine Solbach, Knut Engels, Mahdi Rezai, Karel Dohnal, Hans Tesch, Martin L. Hansmann, Christoph Salat, Michaela Beer, Andreas Schneeweiss, Peter Sinn, Agnes Bankfalvi, Silvia Darb-Esfahani, Gunter von Minckwitz, Bruno V. Sinn, Ralf Kronenwett, Karsten Weber, Carsten Denkert, & Sibylle Loibl"]},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.1988 -"],"origin":[{"dateIssuedKey":"2023","publisher":"Elsevier ; Lippincott Williams & Wilkins ; Ovid ; Nature Publishing Group","dateIssuedDisp":"2023-","publisherPlace":"Amsterdam ; Hagerstown, Md. ; [Erscheinungsort nicht ermittelbar] ; London"}],"title":[{"subtitle":"an official journal of the United States and Canadian Academy of Pathology (USCAP)","title":"Modern pathology","title_sort":"Modern pathology"}],"recId":"326643419","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"issue":"4","year":"2018","text":"31(2018), 4, Seite 607-615","extent":"9","volume":"31","pages":"607-615"},"id":{"zdb":["2041318-X"],"issn":["1530-0285"],"eki":["326643419"]},"note":["Gesehen am 15.01.26","Fortsetzung der Druck-Ausgabe"],"disp":"Clinical relevance and concordance of HER2 status in local and central testing an analysis of 1581 HER2-positive breast carcinomas over 12 yearsModern pathology"}],"note":["Published: 22 December 2017","Gesehen am 15.11.2018"],"id":{"eki":["1583752137"],"doi":["10.1038/modpathol.2017.171"]},"language":["eng"],"person":[{"display":"Pfitzner, Berit Maria","role":"aut","given":"Berit Maria","family":"Pfitzner"},{"role":"aut","display":"Schneeweiss, Andreas","family":"Schneeweiss","given":"Andreas"},{"given":"Peter","family":"Sinn","role":"aut","display":"Sinn, Peter"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a PFITZNERBECLINICALRE2018 | ||